DM

Darryl Maher

Dr Maher adds global biopharmaceutical and commercialisation capability to the Cynata board, with over 23 years' experience with CSL Limited. CSL is one of the developers of biologic pharmaceutical products and has a market capitalisation of A$130 billion. Dr Maher has had a career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple drug products from initiation through to clinical development and ultimately to commercialisation.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CYP
CYP
29/11/25116,666N/A220,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CYP
CYP
01/04/25
Expiry
25,000$0.205$5,125Options expired
CYP
CYP
23/01/25
Issued
66,666$0.180$11,999Placement
CYP
CYP
20/11/23
Issued
220,000$0.120$26,400Issue of options
CYP
CYP
01/06/23
Issued
25,000$0.135$3,375Issue of options
CYP
CYP
01/06/23
Issued
50,000$0.215$10,750Placement